JAC Advance Access originally published online on November 16, 2004
Journal of Antimicrobial Chemotherapy 2004 54(6):1085-1091; doi:10.1093/jac/dkh485
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.54 no.6 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model
1 Laboratory of Experimental Infection, Infectious Disease Service;; 2 Microbiology Department, Hospital de Bellvitge, University of Barcelona, C/Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
* Correspondence address. C/Diputació 89–91, 4° 4a, 08015 Barcelona, Spain. Tel: +34-93-2607625; Fax: +34-93-2607637; Email: amontero{at}gencat.net
Objectives: Successful therapy of carbapenem-resistant Acinetobacter baumannii strains has been reported with colistin, but recently we argued against its use as monotherapy because of the poor results obtained in a mouse pneumonia model. Our aim was to identify antibiotic combinations that were valid therapeutic alternatives in the same model.
Methods: We used two carbapenem-resistant A. baumannii strains (D and E; MICs of imipenem, 8 and 512 mg/L, respectively). MICs of tobramycin, rifampicin and colistin for both strains were 8, 8 and 0.5 mg/L, respectively.
Results: In infections caused by strain D, lung bacterial counts (log10 cfu/g, mean ± S.D.) were: controls (10.86±0.25), imipenem (5.99±0.59, P < 0.05 versus controls), and colistin (10.43 ± 1.09); imipenem + tobramycin was the most active combination (5.46±0.62, P < 0.05 versus controls). In infections caused by strain E, results were: controls (10.82±0.33), rifampicin (5.62±0.26, P < 0.05 versus controls), colistin (8.38±1.22, P < 0.05 versus controls), and imipenem (11.01±0.2); rifampicin + imipenem (3.79±0.99) and rifampicin + tobramycin (3.96±0.30) were the most active combinations (P < 0.05); results with rifampicin + colistin (5.59±1.17) were similar to those with rifampicin alone.
Conclusions: Our data indicate that imipenem can still be the best alternative for carbapenem-resistant A. baumannii infections with moderate levels of imipenem resistance, preferably combined with aminoglycosides. For strains highly resistant to imipenem, a combination of rifampicin with imipenem, tobramycin or colistin may be useful, if resistance to rifampicin is only moderate.
Keywords: multiresistant , A. baumannii , experimental , animals
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Aoki, K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa J. Antimicrob. Chemother., March 1, 2009; 63(3): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Russo, J. M. Beanan, R. Olson, U. MacDonald, N. R. Luke, S. R. Gill, and A. A. Campagnari Rat Pneumonia and Soft-Tissue Infection Models for the Study of Acinetobacter baumannii Biology Infect. Immun., August 1, 2008; 76(8): 3577 - 3586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Landman, C. Georgescu, D. A. Martin, and J. Quale Polymyxins Revisited Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Peleg, H. Seifert, and D. L. Paterson Acinetobacter baumannii: Emergence of a Successful Pathogen Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo Global Challenge of Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484. [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Tan, L. S. Y. Ng, E. Tan, and G. Huang In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates J. Antimicrob. Chemother., August 1, 2007; 60(2): 421 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Song, S. Y. Kee, I. S. Hwang, Y. B. Seo, H. W. Jeong, W. J. Kim, and H. J. Cheong In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii J. Antimicrob. Chemother., August 1, 2007; 60(2): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saballs, M. Pujol, F. Tubau, C. Pena, A. Montero, M. A. Dominguez, F. Gudiol, and J. Ariza Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections J. Antimicrob. Chemother., September 1, 2006; 58(3): 697 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Pachon-Ibanez, F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, and A. Pascual Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam J. Antimicrob. Chemother., September 1, 2006; 58(3): 689 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Wareham, D. C. Bean, C. M. Urban, and J. J. Rahal In Vitro Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., February 1, 2006; 50(2): 825 - 826. [Full Text] [PDF]
|
|